Zacks Research Has Positive Outlook for LABT Q3 Earnings

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) – Analysts at Zacks Research raised their Q3 2026 EPS estimates for Lakewood-Amedex Biotherapeutics in a note issued to investors on Wednesday, August 26th. Zacks Research analyst D. Bautz now anticipates that the company will post earnings of $0.81 per share for the quarter, up from their previous estimate of $0.56. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $2.52 per share. Zacks Research also issued estimates for Lakewood-Amedex Biotherapeutics’ Q4 2026 earnings at $0.76 EPS and FY2026 earnings at $4.96 EPS.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its quarterly earnings results on Friday, August 14th. The company reported ($2.75) EPS for the quarter.

Several other research firms also recently commented on LABT. Weiss Ratings initiated coverage on shares of Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They issued a “sell (e-)” rating on the stock. Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Trading Up 10.4%

Shares of NASDAQ LABT opened at $2.76 on Wednesday. Lakewood-Amedex Biotherapeutics has a 52 week low of $1.66 and a 52 week high of $98.20. The firm has a 50 day moving average price of $2.49. The stock has a market capitalization of $6.54 million and a price-to-earnings ratio of -0.58.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.